

Active Biotech's nomination committee appointed

In accordance with a decision made by the Annual General Meeting held on May 28, 2025, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2025, and the Chairman of the Board.

If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Based on the above, the Nomination Committee is composed with participants representing the largest shareholders in Active Biotech as of September 30, 2025, and consists of:

Michael Shalmi, chairman
Mats Arnhög, MGA Holding
Peter Thelin, Sjuenda Holding
Petter Wingstrand, T-bolaget

For the 2026 Annual General Meeting, the Nomination Committee shall prepare and submit proposals regarding the Chairman of the AGM, the number of Board members, a Chairman and Board members elected by the AGM, the fees and other renumerations to Board members and Board committee's, number of auditors, the auditor, fees to auditors and election of a Nomination Committee.

For further information, please contact:

Helén Tuvesson, *CEO*, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, *CFO*, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. A clinical Phase Ib/IIa study in multiple myeloma has been concluded. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

Attachments

Active Biotech's nomination committee appointed